People Round-up: Allianz, Arch, Axa XL, Manulife, Swiss Re
July 31 2020 by Andrew Tjaardstra
-
Australian doctors’ mutual MDA National appoints Tim Plant as chief executive
- November 22
Sydney-based Plant previously held senior executive roles at organisations including Elders, QBE, icare, Zurich, and, most recently, IAG.
-
Aon names Mike Yao as Asia director for life reinsurance analytics
- November 22
In his new role, Singapore-based Yao will contribute to the development and articulation of the broker's analytics value proposition for its APAC clients.
-
Chaucer Singapore expands political risk underwriting with Axa XL hire
- November 22
The China Re-owned Lloyd's player has appointed Jonathan Ng as class underwriter in political risk.
-
Aon promotes Singapore-based Magnus Roe to global chief data and analytics officer
- November 21
Roe, who was global head of strategy, risk capital analytics for the broker, will integrate AI, data governance and analytics into the broker's data and analytics strategy, reporting to Aon COO Mindy Simon.
-
BHSI | Managing non-Asian exposure in long-tail lines
While US-exposed business can look attractive to Asian carriers, managing the volatility around the long-term results and the ability to model those losses are crucial, say BHSI’s Marc Breuil and Marcus Portbury.
-
Sedgwick | To Handle CAT Claims Well, Multi-Step Preparation is Key
When it comes to risk, it’s not a matter of “if” it’s a matter of “when” an event will occur.
-
HSBC Asset Management | Is it time to relook at Asian currency bonds?
With diversification and performance high on investors’ agendas, it seems a good time for global portfolios to revive allocations in Asian local currency bonds – including Hong Kong dollar (HKD) bonds.
-
PineBridge Investments | Why Asian insurers are exploring private credit and CLOs
The recent rollout of risk-based capital regimes across Asia calls for a closer alignment between insurers’ assets and liabilities. We explore potential ways to maintain a healthy investment yield and robust returns on regulatory capital.
